• "Living with a question mark": psychosocial experience of Portuguese young adults at risk for hereditary amyloid transthyretin amyloidosis with polyneuropathy
• 99mTc-PYP and 68Ga-FAPI PET/CT Images of Hereditary Transthyretin Amyloidosis With Cardiac Involvement
• A case of mixed hereditary gelsolin amyloidosis and hydroxychloroquine induced myopathy
• A comprehensive review on the current status of CRISPR based clinical trials for rare diseases
• A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy
• A Novel Symptomatic Lecithin-Cholesterol Acyltransferase Gene Mutation With Corneal Amyloidosis
• Adherence and persistence to tafamidis treatment among Medicare beneficiaries in the presence of a patient assistance program
• Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings
• Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis: Insights From THAOS
• Altered connectivity of central autonomic network: effects of dysautonomia in hereditary transthyretin amyloidosis with polyneuropathy
• Amyloid Neuropathy: From Pathophysiology to Treatment in Light-Chain Amyloidosis and Hereditary Transthyretin Amyloidosis
• Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system
• Anti-PEG antibodies associated with reduced therapeutic effect of patisiran in patients with hereditary transthyretin amyloidosis
• Assessment of incidental cardiac uptake in bone scintigraphy across Spain: The ECCINGO study
• Brain MRI in patients with V30M hereditary transthyretin amyloidosis
• Cardiac amyloidosis and aortic stenosis: what do we know?
• Cardiopulmonary exercise testing in transthyretin amyloid cardiomyopathy patients: a long-term follow-up study
• Case Report: A rare transthyretin mutation p.D58Y in a Chinese case of transthyretin amyloid cardiomyopathy
• Clinical and Cardiovascular Magnetic Resonance Imaging Features of Cardiac Amyloidosis
• Clinical and genetic profiles of patients with hereditary and wild-type transthyretin amyloidosis: the Transthyretin Cardiac Amyloidosis Registry in the state of Sao Paulo, Brazil (REACT-SP)
• Clinical case of generalized amyloidosis (ATTR-amyloidosis) with a progressive course of chronic heart failure. Case report
• Clinical outcomes of catheter ablation for atrial fibrillation, atrial flutter, and atrial tachycardia in wild-type transthyretin amyloid cardiomyopathy: a proposed treatment strategy for catheter ablation in each arrhythmia
• Clinicopathological Features of Amyloid Neuropathy: A Four Decade Experience
• Comparison of Clinical and Genetic Characteristics of Familial Mediterranean Fever Patients Among Adult Age Groups
• Correction to: Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy
• Could tocilizumab be used in familial Mediterranean Fever? A systematic review
• Cryo-EM confirms a common fibril fold in the heart of four patients with ATTRwt amyloidosis
• Current Perspectives on Atrial Amyloidosis: A Narrative Review
• Cutaneous amyloidosis mimicking basal cell carcinoma: a case series and literature review
• Defining echocardiographic predictors of outcome in cardiac amyloidosis by subtype
• Diagnostic Modalities in the Detection of Cardiac Amyloidosis
• Diagnostic Value of Late Gadolinium Enhancement at Cardiac Magnetic Resonance to distinguish Arrhythmogenic Right Ventricular Cardiomyopathy from Differentials
• Diagnostic value of late gadolinium enhancement at cardiovascular magnetic resonance to distinguish arrhythmogenic right ventricular cardiomyopathy from differentials
• Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis
• Distinctive Deposition Patterns of Sporadic Transthyretin-Derived Amyloidosis in the Atria: A Forensic Autopsy-Based Study
• Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
• Emerging multisystem biomarkers in hereditary transthyretin amyloidosis: a pilot study
• Epidemiology, diagnosis, and management of cardiac amyloidosis
• Eplontersen: a promising breakthrough in treating hereditary transthyretin amyloidosis-related polyneuropathy
• Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis
• Examining the Difficulties in Identifying and Handling Cardiac Amyloidosis; Acquiring Important Knowledge and Robust Treatment Methods
• Exercise Hemodynamics and Mitochondrial Oxidative Capacity in Disease Stages of Wild-Type Transthyretin Amyloid Cardiomyopathy
• Experience with tafamidis in peritoneal dialysis for a patient diagnosed with transthyretin cardiac amyloidosis
• EXPRESS: Epidemiology, Diagnosis and Management of Cardiac Amyloidosis
• Gender Differences in the Evaluation and Management of New Acute CHF Due to ATTRwt Cardiac Amyloidosis
• Genotype-Phenotype Correlations in ATTR Amyloidosis: A Clinical Update
• Hereditary Amyloidosis: Insights Into a Fibrinogen A Variant Protein
• Hereditary neuropathic itch caused by gelsolin mutation
• Hereditary Transthyretin Amyloidosis (hATTR) with Polyneuropathy Clusters Are Located in Ancient Mining Districts: A Possible Geochemical Origin of the Disease
• Hereditary transthyretin amyloidosis presenting with prominent autonomic dysfunction
• Hereditary transthyretin amyloidosis with hydrocephalus at 27 years old: A case report
• Hereditary transthyretin amyloidosis: a myriad of factors that influence phenotypic variability
• How, when, and who: Composing the puzzle of family screening in hereditary cardiac amyloidosis
• Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis
• IL-1 Inhibitors in the Treatment of Familial Mediterranean Fever: Treatment Indications and Clinical Features in a Large Real-World Cohort
• Incremental prognostic utility of congestion markers in cardiac transthyretin amyloidosis
• Inverse correlation between age of onset and myocardial amyloid deposition quantified by ^99mTc-PYP scintigraphy in patients with wild-type transthyretin amyloid cardiomyopathy
• Islands and Neurology: An Exploration into a Unique Association
• Late initiation of anakinra can induce complete renal response in renal AA amyloidosis secondary to Familial Mediterranean Fever
• Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs
• Mispacking of the F87 sidechain drives aggregation-promoting conformational fluctuations in the subunit interfaces of the transthyretin tetramer
• Modeling transthyretin (TTR) amyloid diseases, from monomer to amyloid fibrils
• Mosaic Loss of the Y Chromosome Is Enriched in Patients With Wild-Type Transthyretin Cardiac Amyloidosis and Associated With Increased Mortality
• Native State Stabilization of Amyloidogenic Proteins by Kinetic Stabilizers: Inhibition of Protein Aggregation and Clinical Relevance
• Non-Immunoglobulin Amyloidosis-Mediated Kidney Disease: Emerging Understanding of Underdiagnosed Entities
• Nuclear imaging techniques for cardiac amyloidosis
• Olpasiran Pharmacodynamic Study: Ensuring We Go a Mile Deep But More Than an Inch Wide
• Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real-World Data
• Palinacousis in amyloidosis: exploring the hallucinatory phenomenon in brain pathology-a case report
• Pars-plana vitrectomy for the treatment of vitreous amyloid in patients with hereditary transthyretin amyloidosis
• Patisiran for the treatment of patients with p.Ile88Leu hereditary transthyretin amyloidosis: an Italian real-life experience
• Phenotype and prognostic factors in geriatric and non-geriatric patients with transthyretin cardiomyopathy
• Phospholipid-induced secondary structural changes of lysozyme polymorphic amyloid fibrils studied using vacuum-ultraviolet circular dichroism
• Predictors of developing renal dysfunction following diagnosis of transthyretin cardiac amyloidosis
• Prevalence, Characteristics, and Impact on Prognosis of Aortic Stenosis in Patients With Cardiac Amyloidosis
• Race and Socioeconomic Status Impact Diagnosis and Clinical Outcomes in Transthyretin Cardiac Amyloidosis
• Radionuclide Imaging of Cardiac Amyloidosis: An Update and Future Aspects
• Recent advances in the diagnostic methods and therapeutic strategies of transthyretin cardiac amyloidosis
• Recurrent ventricular tachycardia in a patient with A19D mutation-associated hereditary transthyretin amyloidosis: a case report
• Renal tubular acidosis in hereditary transthyretin amyloidosis (ATTRv)
• Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval
• RNA Interference Therapeutics for Hereditary Amyloidosis: A Narrative Review of Clinical Trial Outcomes and Future Directions
• SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy
• Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review
• Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis
• Structural and thermodynamic characterization of a highly amyloidogenic dimer of transthyretin involved in a severe cardiomyopathy
• Successful Treatment with Patisiran in Amyloid Polyneuropathy Harboring His90Asn Mutation in the <em>TTR</em> Gene
• Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform
• Systemic Diseases and Heart Block
• Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones
• Teaching NeuroImage: Scalloped Pupils in a Transplant Patient With Hereditary Transthyretin Amyloidosis
• Temporal implementation of a regional referral pathway in transthyretin cardiac amyloidosis: Emilia-Romagna experience
• The effectiveness of anti-interleukin-1 therapy on subclinical inflammation parameters during the attack-free period in familial Mediterranean fever patients: A case-control study
• The Most Predictive Red Flags for Suspecting Cardiac Amyloidosis in Patients with Heart Failure with Preserved Ejection Fraction
• The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis
• Thromboembolic and bleeding risk in cardiac amyloidosis
• Transthyretin Cardiac Amyloidosis in an Elderly Male With Heart Failure Intolerant to Guideline-Directed Medical Therapy
• Transthyretin monomers: a new plasma biomarker for pre-symptomatic transthyretin-related amyloidosis
• Ultrasensitive Proteomics of Trace Cardiac Tissues with Anchor-Nanoparticles
• Wild-Type Transthyretin Amyloidosis: A Prevalent and Underdiagnosed Cause of Heart Failure With Preserved Ejection Fraction